

November 10, 2022

BrightPath to Update the Pre-clinical Data of BP1210 and BP1212 at SITC 2022

Tokyo, Japan - November 10, 2022/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics, today announced a presentation of the pre-clinical data on a novel Bispecific antibodies that block TIM-3 (BP1210) and a novel Bispecific antibodies that block TIM-3 and CD39 (BP1212) at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2022, November 8-12, Boston).

The presentation is available on the websites of [BrightPath](#)

BrightPath's abstract is as follows:

Title: Bispecific antibodies that block TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms.
(Abstract number:1364)

The presentation describes:

- **BP1210 and BP1212 are bispecific antibodies developed using next-generation antibody engineering technology and exert their antitumor effects by simultaneously recognizing and inhibiting immunosuppressive molecules, TIM-3 and CD39.**
- **BP1210 strongly activates cytotoxic T cells that attack cancer cells, and enhances its anti-tumor effects. By the bispecificity, significantly higher anti-tumor activity was achieved than other anti-TIM-3 antibodies (monospecific antibodies) under clinical development.**
- **BP1212 exerts anti-tumor effects by targeting CD39 and TIM-3-positive cells and blocking the immunosuppressive functions of CD39 and TIM-3. By the dual binding to targets, BP1212 strongly inhibits target molecules with higher specificity in recognition of target cells. Simultaneous dual binding and inhibition enhances and maintains high antitumor activity of cytotoxic T cells more than either monoclonal antibody alone.**

TIM-3, an immune checkpoint molecule, is expressed on activated T cells and dendritic cells that play a central role in anti-tumor immunity. TIM-3 attenuates the function of immune cells by responding with multiple molecules including phosphatidylserine, galectin-9, HMGB1, CEACAM1, etc. released by cancer cells for immunosuppression and escape. Although the innate function of TIM-3 is to control excessive immune responses that causes inflammation and tissue damages, it also suppresses anti-tumor immune response in cancer patients. TIM-3 antibodies in clinical development to date have limited anti-tumor efficacy due to their mono-specificity, which does not sufficiently block the immunosuppressive function of TIM-3 triggered by multiple ligands. Using bispecific antibody technology, we have developed a biparatopic antibody, BP1210, which strongly inhibits immune-suppressive signals by TIM-3

BP1212 is a bispecific antibody that simultaneously inhibits TIM-3 and CD39. TIM-3 and CD39

are induced for self-suppression in cytotoxic T cells that attack cancer cells, but cancer cells abuse these molecules for immune escape and proliferation. BP1212 robustly enhances the cytotoxic activity of intra-tumoral T cells against cancer cells by inhibiting the function of these two molecules and releasing the brake of tumor immunity. In addition, BP1212 is a highly engineered bispecific antibody with enhanced target specificity and inhibiting potential through a precise molecular design that allows simultaneous recognition of two target molecules.

About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently in clinical trials, immunomodulatory antibodies and new drug targeted at cancer specific neoantigens.

For more information, visit www.brightpathbio.com/english/index.html.

Forward-Looking Statements:

This news release contains forward-looking statements that are based on the current expectations and beliefs of BrightPath. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. BrightPath cautions that these forward-looking statements do not guarantee our future financial results but involve risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. These forward-looking statements speak only as of the date of this press release and BrightPath assumes no duty to update forward-looking statements, except as may be required by law.

Investor and Media Contact:

+81-3-5840-7697

irpr@brightpathbio.com

www.brightpathbio.com/english/index.html